HC Wainwright Has Positive Estimate for LifeMD Q4 Earnings

LifeMD, Inc. (NASDAQ:LFMD) – HC Wainwright lifted their Q4 2027 earnings per share (EPS) estimates for LifeMD in a research report issued on Friday, August 7th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.17 for the quarter, up from their prior forecast of $0.15. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.37) per share.

LifeMD (NASDAQ:LFMD) last posted its earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%.The business had revenue of $47.28 million for the quarter, compared to analyst estimates of $49.16 million.

LFMD has been the subject of several other reports. BTIG Research cut their price objective on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. B. Riley Financial lowered their price objective on LifeMD from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings reissued a “sell (d)” rating on shares of LifeMD in a report on Tuesday, August 4th. UBS Group restated a “buy” rating on shares of LifeMD in a research note on Wednesday, May 27th. Finally, Mizuho set a $7.00 price objective on shares of LifeMD in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.57.

LifeMD Price Performance

Shares of LFMD opened at $3.46 on Friday. The firm has a market capitalization of $166.77 million, a PE ratio of -69.19 and a beta of 2.02. The company’s 50-day moving average is $4.29 and its 200-day moving average is $3.97. LifeMD has a fifty-two week low of $2.56 and a fifty-two week high of $7.32.

Hedge Funds Weigh In On LifeMD

Several hedge funds and other institutional investors have recently made changes to their positions in LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of LifeMD by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after acquiring an additional 2,235 shares in the last quarter. Creative Planning acquired a new stake in shares of LifeMD in the 2nd quarter valued at $272,000. JPMorgan Chase & Co. increased its stake in shares of LifeMD by 581.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of LifeMD by 187.4% during the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after buying an additional 6,614 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in LifeMD by 8.7% in the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock valued at $730,000 after buying an additional 4,281 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.